Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

The data, collected during the transition from intravenous (IV) to oral levosimendan in the open-label extension (OLE) of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) trial, were presented at the Heart Failure Society of America (HFSA) Scientific Sessions 2022

News | Heart Failure

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

October 13, 2022 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing, and ...

October 13, 2022

the U.S. Patent and Trademark Office has issued to the University of Iowa Research Foundation ("UIRF") U.S. Patent No. 11,414,704 titled COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE, which is exclusively licensed to the Company from UIRF

News | Heart Failure

Cardio Diagnostics Announces Issuance of U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

October 13, 2022 — Cardio Diagnostics, Inc. , a pioneering precision cardiovascular testing company, announced that the ...

October 13, 2022

Zach Williams wanted to be a cancer researcher, but quick success in another area refocused his research on cardiovascular science. He was awarded a National Institutes of Health grant to fund his research for two years. Image courtesy of Clayton Metz/Virginia Tech.

News | Heart Failure

Virginia Tech Graduate Student Earns NIH Support to Explore Promising Heart Finding

October 13, 2022 — Zach Williams thought he’d become a cancer researcher when he joined Virginia Tech’s Translational ...

October 13, 2022

Videos | TCT

VIDEO: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

At TCT 2022, Deepak Bhatt, MD, MPh, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's ...

October 13, 2022

The Delphi study results show Philips’ integrated echocardiography solution provides the tools required for baseline risk stratification and monitoring of cardio-oncology patients as recommended by the latest European Society of Cardiology (ESC) guidelines

News | Heart Failure

Panel of Experts Highlights Clinical and Operational Benefits of Philips’ Integrated Echocardiography Solution

October 12, 2022 — Following the recent European Society of Cardiology (ESC) Congress in Barcelona, Spain last month, ...

October 12, 2022

Study investigates metformin and other candidate drugs through a network medicine approach

News | Heart Failure

Cleveland Clinic Researchers Identify Diabetes Drug Metformin as Potential Atrial Fibrillation Treatment in Collaborative Research

October 12, 2022 — Cleveland Clinic researchers have identified a common diabetes medication, metformin, as a possible ...

October 12, 2022

Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.

News | Cardiovascular Clinical Studies

ELANA Heart Bypass Solution Shows Promising Preliminary Results in First-in-Human Trials

October 11, 2022 — The preliminary results of the first-in-human (FIH) trials for the innovative ELANA Heart Bypass ...

October 11, 2022

Researchers from the University of Minnesota Medical School found that patients with certain features on magnetic resonance imaging (MRI) of the heart are at much higher risk for cardiac sarcoidosis-related adverse outcomes.

News | Cardiac Imaging

Identifying Patients with Sarcoidosis at Risk for Bad Cardiac Outcomes

October 11, 2022 — Researchers from the University of Minnesota Medical School found that patients with certain features ...

October 11, 2022

Grant Proceeds Will Support Pre-Clinical Studies

News | Stents Bioresorbable

Efemoral Medical Awarded Phase II SBIR Grant from NIH to Advance Treatment for Peripheral Artery Disease

October 11, 2022 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced that it ...

October 11, 2022

News | Stroke

Identifying How Inflammation Affects Stroke Recovery

October 7, 2022 — A new research grant will enable University of Cincinnati researchers to learn more about how ...

October 07, 2022

This is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, marking a milestone for future clinical research

News | Heart Failure

ChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

October 7, 2022 — ChromaDex Corp. announced promising findings from a clinical study, as reported in the peer-reviewed ...

October 07, 2022

Results presented at the Heart Failure Society of America Annual Scientific Meeting

News | Heart Failure

Cleveland Clinic-Led Trial Finds That Increasing Salt Intake Does Not Affect Patients Hospitalized with Congestive Heart Failure During Treatment

October 6, 2022 — Findings from a Cleveland Clinic-led trial show that increasing the salt intake by mouth for patients ...

October 06, 2022

Rutgers study finds post-surgical hospitalization rates from left ventricular assist devices varied by socioeconomic factors

News | Heart Failure

Lower-Income Patients with Heart Pumps More Likely Hospitalized with Major Bleeding, Infection or Heart Failure

October 6, 2022 — The complications experienced by heart failure patients implanted with a left ventricular assist ...

October 06, 2022

CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with treatment-resistant hypertension as part of the late-breaking science session

News | Hypertension

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific Sessions

October 5, 2022 — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from ...

October 05, 2022

New analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart failure

News | Heart Failure

New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100 Lowers Hospital Length of Stay by 55%

October 4, 2022 — Newswise — Daxor Corporation, a global leader in blood volume measurement technology, today announces ...

October 04, 2022